Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
AGEN1571 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Dose Escalation: AGEN1571 | EXPERIMENTAL | Participants will receive AGEN1571 monotherapy. |
| Dose Escalation: AGEN1571 + Balstilimab | EXPERIMENTAL | Participants will receive AGEN1571 with balstilimab. |
| Dose Escalation: AGEN1571 + Botensilimab | EXPERIMENTAL | Participants will receive AGEN1571 with botensilimab. |
| Dose Escalation: AGEN1571 + Balstilimab + Botensilimab | EXPERIMENTAL | Participants will receive AGEN1571 with balstilimab and botensilimab. |
| Dose Expansion | EXPERIMENTAL | AGEN1571 administered at the RP2D for monotherapy or any combination therapy. |
| Name | Type | Description |
|---|---|---|
| AGEN1571 | DRUG | A fully human monoclonal immunoglobulin-like transcript antagonist antibody administered intravenously. |
| Balstilimab | DRUG | A fully human monoclonal programmed cell death protein 1 antagonist antibody administered intravenously. |
| Botensilimab | DRUG | A fully human fragment crystallizable-enhanced monoclonal cytotoxic T lymphocyte antigen 4 antibody administered intravenously. |
Inclusion Criteria: 1. Voluntarily agree to participate by giving signed, dated, and written informed consent prior to any study-specific procedures (participation in genetic testing is optional). 2. Histologically confirmed diagnosis of a solid tumor that is currently metastatic or locally advance...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 3 | PHASE2 | Pembrolizumab, Gardasil 9 |
| Incyte Corporation | INCY | 1 | PHASE2 | Retifanlimab |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115 |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | Aldesleukin |
| AstraZeneca PLC | AZN | 1 | - | Trastuzumab deruxtecan |
AGEN1571 is an investigational small molecule developed by Agenus Inc. for the treatment of advanced solid tumors. It is designed to target ILT2, a protein receptor involved in immune regulation. AGEN1571 has been studied in a Phase 1 clinical trial and is not approved for any indication.
AGEN1571 is being developed for the treatment of advanced solid tumors. It is an investigational therapy and has not been approved for any cancer indication. The Phase 1 study enrolled 22 participants with advanced solid tumors in the United States to evaluate the drug in this patient population.
AGEN1571 targets ILT2, a protein receptor. ILT2 is an inhibitory receptor expressed on certain immune cells, and targeting it is intended to modulate immune responses against tumors. The drug is a small molecule designed to bind ILT2 as part of its mechanism in advanced solid tumor treatment.
AGEN1571 is being developed by Agenus Inc., a biopharmaceutical company whose common stock trades under the ticker symbol AGEN. Agenus is responsible for the clinical development of the drug, including the completed Phase 1 trial in participants with advanced solid tumors.
AGEN1571 is in Phase 1 clinical development. A Phase 1 trial has been completed, evaluating the drug in participants with advanced solid tumors. The study enrolled 22 participants and was conducted in the United States. AGEN1571 is investigational and has not received FDA approval.
AGEN1571 has been evaluated in one clinical trial, NCT05377528, titled Study of AGEN1571 in Participants With Advanced Solid Tumors. This Phase 1 trial is completed and enrolled 22 participants with advanced solid tumors in the United States. It was a controlled study without randomization or double blinding.